GlassScriptPhysician profile
Elisa Davis
NPI 1447710157
$507.69
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $174.82 | 2021 | |
| Amgen INC. | $122.16 | 2021-2022 | |
| Novo Nordisk INC | $65.91 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.95 | 2021 | |
| Bard Peripheral Vascular, INC. | $28.51 | 2022 | |
| Boston Scientific Corporation | $28.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.42 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.